Keros Therapeutics Inc (KROS) - Total Liabilities
Based on the latest financial reports, Keros Therapeutics Inc (KROS) has total liabilities worth $39.20 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Keros Therapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Keros Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Keros Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Keros Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cadiz Inc
NASDAQ:CDZI
|
USA | $117.66 Million |
|
Bredband2 i Skandinavien AB
ST:BRE2
|
Sweden | Skr754.39 Million |
|
Guangzhou Seagull Kitchen And Bath Products Co Ltd
SHE:002084
|
China | CN¥1.44 Billion |
|
Zhejiang Tuna Environmental Science & Technology Co Ltd
SHG:603177
|
China | CN¥1.52 Billion |
|
Rejlers AB (publ)
ST:REJL-B
|
Sweden | Skr2.12 Billion |
|
Plano & Plano Desenvolvimento Imobiliário S.A
SA:PLPL3
|
Brazil | R$2.84 Billion |
|
Airsculpt Technologies Inc
NASDAQ:AIRS
|
USA | $91.74 Million |
|
BayCom Corp
NASDAQ:BCML
|
USA | $2.26 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Keros Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Keros Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 29.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Keros Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Keros Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Keros Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $44.33 Million | +17.25% |
| 2023-12-31 | $37.81 Million | +28.80% |
| 2022-12-31 | $29.36 Million | +143.09% |
| 2021-12-31 | $12.08 Million | +56.40% |
| 2020-12-31 | $7.72 Million | +40.30% |
| 2019-12-31 | $5.50 Million | -62.44% |
| 2018-12-31 | $14.65 Million | -- |
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias… Read more